PRESS RELEASE

Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021

- Presentation of five scientific abstracts selected for poster presentations at the AASLD The Liver Meeting™ 2021 by Prof. Nezam Afdhal and Prof. Jörn Schattenberg
- Update on the current NASH landscape by Prof. Nezam Afdhal
- Update on Inventiva's Phase II clinical trial evaluating lanifibranor in patients with type 2 diabetes (T2D) and non alcoholic fatty liver disease (NAFLD) by Prof. Kenneth Cusi
- Presentation of Inventiva's Phase IIa combination study with lanifibranor and SGLT2 inhibitor empagliflozin in patients with non-cirrhotic NASH and T2D by Prof. Michelle Lai
- Virtual webcast event on November 19, 2021 at 10:30 am (ET) / 4:30 pm (CET)

Daix (France), Long Island City (New York, United States), November 3, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that it will host a webcast event focused on NASH with the participation of four Key Opinion Leaders (KOLs) on November 19, 2021 from The Liver Meeting™ 2021, organized by the American Association for the Study of Liver Diseases (AASLD).

Following an introduction from Frédéric Cren, Chairman, CEO and cofounder of Inventiva and Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, the event will consist of the presentation of five scientific abstracts presented at AASLD The Liver Meeting™ 2021, as well as four presentations focused on the latest news around the development of lanifibranor and various aspects related to NASH. As part of the program, there will be dedicated Q&A sessions.

The Agenda will be as follows:

Corporate update

Speakers: Frederic Cren, CEO and cofounder of Inventiva Pharma and Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva Pharma

Update on Inventiva's NATIV3 Phase III clinical trial in NASH

Speaker: Dr. Michael Cooreman, Chief Medical Officer of Inventiva Pharma

Update on the NASH field

Speaker: Prof. Nezam Afdhal, Harvard Medical School in Boston, Massachusetts and Chief of Hepatology and Director of the Liver Center at Beth Israel Deaconess Medical Center

Overview of the scientific abstracts presented during the AASLD Liver Meeting

Abstract #1: “Lanifibranor treatment improves hepatic steatosis in patients with NASH, evaluated by histological grading and Controlled Attenuation Parameter (CAP)."
Speaker: Prof. Nezam Afdhal, Harvard Medical School in Boston, Massachusetts and Chief of Hepatology and Director of the Liver Center at Beth Israel Deaconess Medical Center

Abstract #2: “Lanifibranor reverses fasting glucose levels to normoglycemia in prediabetic patients with nonalcoholic steatohepatitis (NASH)."
Speaker: Prof. Nezam Afdhal, Harvard Medical School in Boston, Massachusetts and Chief of Hepatology and Director of the Liver Center at Beth Israel Deaconess Medical Center

Abstract #3: “Liver sinusoidal endothelial cell (LSEC) capillarization in NASH and its evolution following lanifibranor treatment: an exploratory study of the NATIVE clinical trial."
Speaker: Prof. Jorn Schattenberg, Director of the Metabolic Liver Research Program at the University Medical Center of Mainz, Germany

Abstract #4: "Treatment response to the PAN-PPAR agonist lanifibranor in the NATIVE study: NASH resolution and fibrosis improvement are correlated."
Speaker: Prof. Jorn Schattenberg, Director of the Metabolic Liver Research Program at the University Medical Center Mainz, Germany

Abstract #5: “Lanifibranor improves NASH, fibrosis and diastolic dysfunction in a hamster preclinical model of diet-induced NASH.”
Speaker: Prof. Jorn Schattenberg, Director of the Metabolic Liver Research Program at the University Medical Center of Mainz, Germany

Update on Phase II clinical trial evaluating lanifibranor in patients with T2DM and NAFLD

Speaker: Prof. Kenneth Cusi, Chief of the Division of Endocrinology, Diabetes & Metabolism, University of Florida

Presentation of Phase IIa combination study with lanifibranor and SGLT2 inhibitor empaglifozin in patients with NASH and T2DM

Speaker: Prof. Michelle Lai, Associate Professor of Medicine, Harvard Medical School in Boston, Massachusetts and Director of NAFLD Center at Beth Israel Deaconess Medical Center

The details to connect to the webcast are as follows:

Date:	Friday, November 19, 2021
Time:	10:30 am - 12:30 pm (ET) / 4:30 pm - 6:30 pm (CET)
Connection details:	Option #1 – Webcast: https://edge.media-server.com/mmc/p/cazp5n7z
	Option #2 – Conference call:
	France: +33 (0) 1 70 70 07 81 Belgium: +32 (0) 2 793 3847 Germany: +49 (0) 69 2222 2625 Netherlands: +31 (0) 20 795 6614 Switzerland: +41 (0) 44 580 7145 United Kingdom: +44 (0) 207 192 8338 United States: +1 646-741-3167
	Access code: **2391734**

The presentation document and the link to the webcast (live and replay) will also be available on Inventiva's website in the "Investors – Investor Presentations" section: http://inventivapharma.com/investors/investor-presentations/.

•••

About the American Association for the Study of Liver Diseases (AASLD)[1]

AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD fosters research that leads to improved treatment options for millions of liver disease patients. We advance the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Lanifibranor is currently being evaluated in a pivotal Phase III clinical trial.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV-157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com

[1] https://www.aasld.org/

Contacts

Inventiva
Pascaline Clerc
VP of Global External Affairs
media@inventivapharma.com
+1 240 620 9175

Brunswick Group
Laurence Frost /
Tristan Roquet Montegon /
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513 1284

Important Notice

This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva's clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, with respect to the anticipated timeline for seeking of regulatory approvals for candidates, or that candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2020 filed with the Autorité des Marchés Financiers on March 15, 2021, the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 15, 202, Amendment No. 1 to our Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 24, 2021, as well as the full-year financial report for the year ended December 31, 2020 for additional information in relation to such factors, risks and uncertainties.

Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.